Blood Biomarkers of Heart Failure and Hypercoagulation to Identify Atrial Fibrillation-Related Stroke

Markus Kneihsl1, Thomas Gattringer1, Egbert Bisping2

  • 1From the Department of Neurology (M.K., T.G., C.E., S.F.-H., S.E., C.H., B.B., B.P., K.N., F.F.).

Stroke
|June 21, 2019
PubMed

Insights

N-terminal pro-brain natriuretic peptide (NT-proBNP) and hypercoagulation markers are linked to atrial fibrillation (AF)-related strokes. Elevated NT-proBNP levels can help identify cryptogenic stroke patients who may have occult AF.

Area of Science:

  • Cardiology
  • Neurology
  • Biomarker Research

Background:

  • Occult atrial fibrillation (AF) is a significant cause of cryptogenic stroke (CS).
  • Prolonged cardiac monitoring for all CS patients is challenging.
  • Biomarkers for heart failure and hypercoagulability may predict AF in CS patients.

Purpose of the Study:

  • To investigate the association of NT-proBNP, D-dimer, and antithrombin-III (AT-III) with AF-related stroke.
  • To evaluate these biomarkers for predicting AF detection in CS patients.

Main Methods:

  • Prospective study of ischemic stroke patients over one year.
  • Etiologic work-up for all patients; extended monitoring (≥72 hours) for CS patients.
  • Blood biomarker levels (NT-proBNP, D-dimer, AT-III) measured within 24 hours of admission.

Main Results:

  • AF-related stroke patients had higher NT-proBNP and D-dimer, and lower AT-III compared to non-cardiac stroke patients.
  • NT-proBNP ≥505 pg/ml showed 93% sensitivity and 72% specificity for AF-related stroke.
  • In CS patients, NT-proBNP ≥505 pg/ml predicted AF detection with 86% accuracy (98% negative predictive value).

Conclusions:

  • NT-proBNP is associated with AF-related stroke and aids in identifying CS patients for monitoring.
  • Lower NT-proBNP levels (<505 pg/ml) suggest a low likelihood of occult AF.
  • Hypercoagulation markers showed a weaker association with AF-related stroke.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
798
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.1K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
737
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
280
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
830
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
232